Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry
The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure Management (ARIADNE) registry will evaluate patient characteristics, practice patterns, outcomes, and healthcare re
https://www.lupop.lu.se/article/management-heart-failure-reduced-ejection-fraction-europe-design-ariadne-registry - 2025-10-05